| Array BioPharma's ARRY-520 Well Tolerated and Demonstrates Preliminary Activity as a Single Agent in Multiple Myeloma Patients (Business Wire) BOULDER, Colo.----Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma. us.rd.yahoo.com |
Chronic-Fatigue Link to Virus Disputed Two groups of researchers studying a potential link between chronic-fatigue syndrome and a virus called XMRV have reached contradictory conclusions, according to people familiar with the findings. online.wsj.com |
EpiCept's Ambitious Pipeline Douglas Cress submits:By vandersonCancer and chronic pain are two of the most widespread conditions afflicting humanity today. Developing therapeutics for either one of these targets is daunting enough for any life sciences company. But EpiCept Corporation (Nasdaq: EPCT), a Tarrytown, New York-based pharmaceutical company, is tackling both. Acute myeloid leukemia (AML) is the most common form of leukemia in adults. According to the National Cancer Institute, approximately 12,000 people in the U.S. will be diagnosed with and 9,000 will die from AML in 2010. An estimated 47,000 patients in the European Union currently suffer from AML. Many AML patients are successfully treated with chemotherapy drugs, typically experiencing complete remission. However, the majority (75-80%) of patients will experience a relapse of leukemia, usually within one to two years. There are currently no approved, effective remission therapies for AML in the U.S.Complete Story » seekingalpha.com |
Troubled Genzyme Looks to Lighten Its Load The Burrill Report submits: By Michael FitzhughGenzyme (GENZ) is selling Genzyme Genetics, its genetics testing unit, to LabCorp, a leading lab test company, for $925 million. The divestiture, paired with a global workforce reduction announced Friday, is a key part of Genzyme's plan for slimming and strengthening the company as it parries Sanofi's (SNY) attempts to acquire it for $18.5 billion—a figure Genzyme has rebuffed as too low. Complete Story » seekingalpha.com |
Let’s make all kids lead-free kids - Video National Campaign Launches to Protect Children and Families from Lead Poisoning feedproxy.google.com |